Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.53 |
| ▸ | BCL9 | O00512 | 4/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152476 | 0.82 | RORC (0.49) | MGLLRORC | |
| SCHEMBL18152479 | 0.80 | MGLL (0.44) | MGLLBCL9CTNNB1RORCBCHE | |
| SCHEMBL18152474 | 0.80 | MGLL (0.44) | MGLLBCL9CTNNB1RORCBCHE | |
| SCHEMBL20021944 | 0.77 | MGLL (0.55) | MGLLROCK2POLB | |
| SCHEMBL19510609 | 0.77 | FFAR4 (0.54) | POLB | |
| SCHEMBL20021961 | 0.75 | CNR1 (0.54) | BCL9CTNNB1CNR1 | |
| SCHEMBL21062556 | 0.72 | MGLL (0.52) | MGLLBCL9CTNNB1BCHE | |
| SCHEMBL21062557 | 0.72 | MGLL (0.52) | MGLLBCL9CTNNB1BCHE | |
| SCHEMBL27815058 | 0.71 | MGLL (0.71) | MGLLROCK2BCHEPOLB | |
| SCHEMBL26110269 | 0.71 | MGLL (0.48) | MGLLBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | MGLL 3288/4885BCL9 1/4885CTNNB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.